034) at time 1 preinjection compared with time 0 pre-exercise. At time 1, elevated levels of muscle soreness and force attenuation were
similar between groups compared with time 0 pre-exercise (P < 0.0001), and similar hypertonic saline-induced pain areas and pain intensity profiles were evident. Conclusion. In comparison with placebo, a single low-dose sublingual pharmacological intervention targeting the processes of sensitization via antagonism of NMDA receptors did not modulate the effects of acute experimentally induced mechanical hyperalgesia, suggesting a higher dose or repeat doses may be required.”
“Purpose Our objective was to estimate preference-based weights for the IWQOL-Lite Fedratinib that reflect the relative importance overweight and obese people place on the domains included in the instrument.
Methods US
residents, 18 years of age or older, who are overweight (BMI = 25.0-29.9) or obese (BMI >= 30) completed an online survey instrument consisting of 12 choice questions. The survey included eight attributes: problems doing usual daily activities, physical symptoms, worry about health, low self-esteem, sexual problems, problems moving around or sitting in public places, teasing or discrimination, and problems at work. Ordered probit was used to estimate importance weights for the attributes and levels.
Results Five hundred and two subjects completed the survey. Sexual problem was the find more most important attribute. The remaining
attributes can be ranked on the order of importance as follows: low self-esteem, physical symptoms, daily activities, teasing or discrimination, GPCR Compound Library research buy moving around or sitting, problems at work, and worry about health.
Conclusions Our results confirm previous findings that weighting the individual items in the IWQOL-Lite by the importance of outcomes to overweight and obese subjects may provide a more meaningful evaluation of the effect of changes in weight on patient well-being than a nonpreference- based measure of HRQOL.”
“Purpose To analyze the association between utility, treatment, and generic and prostate-specific health-related quality of life (HRQoL) among patients with prostate cancer.
Methods In this longitudinal cohort study, we recruited 201 (>= 45 years) newly diagnosed patients with prostate cancer from urology clinics of an urban academic hospital. Participants completed Quality of Wellbeing (QWB-SA), generic (SF-36), and prostate-specific (UCLA-PCI) HRQoL surveys prior to treatment and up to 24 months post-treatment. Clinical and demographic data were obtained via medical chart review, and utility scores were computed using QWB-SA. To analyze the relationship between treatment and utility, we used linear mixed effects models, after adjusting for covariates and propensity score. Similar models were used to examine the association between generic and prostate-specific HRQoL and utility.